Search clinical trials for: pembrolizumab, gemcitabine and cisplatin

Total 7660 results

UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Bladder Cancer

United States
Gyeongsang National University Hospital
Samsung Medical Center; Dong-A University; Chung-Ang University

Terminated

Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

Korea, Republic of
National University Hospital, Singapore

Not yet recruiting

Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

Nasopharyngeal Cancer

Singapore
3D Medicines (Sichuan) Co., Ltd.

Not yet recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Biliary Tract Neoplasms
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaborators

Active, not recruiting

GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck Neoplasm

China
Kansai Hepatobiliary Oncology Group

Completed

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Biliary Tract Cancer

Japan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Active, not recruiting

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Italy, Spain, Canada, France, Puerto Rico
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

HER2 Gene Mutation

China
Institut du Cancer de Montpellier - Val d'Aurelle

Active, not recruiting

A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer (GETUGV04)

Infiltrating Bladder Urothelial Carcinoma

France
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed Carcinoma

United States, Guam, Puerto Rico
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
BicycleTx Limited

Recruiting

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Metastatic Urothelial Cancer

United States
M.D. Anderson Cancer Center

Recruiting

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

United States
Sun Yat-sen University

Unknown

GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma

China
Barmherzige Brüder Vienna

Completed

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer

Bladder Cancer

Austria
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Akeso

Recruiting

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China, United States, Australia, Brazil, Canada
Second Affiliated Hospital, School of Medicine,...
The First Affiliated Hospital of Zhengzhou University; The Affiliated Tumor...

Recruiting

Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Hua Li

Recruiting

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

China
Kansai Hepatobiliary Oncology Group

Completed

Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer

Biliary Tract Cancer

Japan
First People's Hospital of Foshan

Unknown

Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hannover Medical School

Completed

PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) (PiCCA)

Cholangiocarcinomas

Germany
Sun Yat-sen University
Peking University; Zhejiang Cancer Hospital; Fudan University; West China Hospital and other collaborators

Unknown

Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
University College, London
Eli Lilly and Company

Completed

Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors (ABC-02)

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United Kingdom
Tata Memorial Centre

Recruiting

Radiation Therapy in Unresectable Gall Bladder Cancer (RUGB)

Gall Bladder Cancer

India
Kansai Hepatobiliary Oncology Group

Completed

A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy

Biliary Tract Cancer

Japan
National Taiwan University Hospital
Merck Sharp & Dohme LLC

Recruiting

Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence

Esophageal Squamous Cell Carcinoma

Taiwan
Seagen Inc.
Merck Sharp & Dohme LLC; RemeGen Co., Ltd.

Recruiting

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Urothelial Carcinoma

United States, Canada, Australia, Singapore
Spanish Lung Cancer Group

Terminated

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma (BREC)

Non Small Cell Lung Cancer | BRCA1 Mutation

Spain
Peking Union Medical College Hospital

Recruiting

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Biliary Tract Neoplasms Immunotherapy

China
European Organisation for Research and Treatment...

Completed

Pembrolizumab in Biliary Tract Cancer

Metastatic Cancer | Advanced Cancer | Biliary Tract Cancer | Gallbladder Cancer

United Kingdom, Spain, Germany
Chaosu Hu
Zhejiang Cancer Hospital; Fujian Cancer Hospital; Affiliated Hospital of Jiangnan... and other collaborators

Recruiting

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Nasopharyngeal Carcinoma

China
The European Uro-Oncology Group
Centre for Human Drug Research, Netherlands

Recruiting

Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (URANUS)

Upper Tract Urothelial Carcinoma

Norway, Spain, Netherlands
Kuwait Cancer Control Center

Recruiting

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Kuwait
Shantou University Medical College

Unknown

Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

Pleural Effusion, Malignant

China
City Clinical Oncology Hospital No 1
Moscow Clinical Scientific Center; Moscow City Oncology Hospital No. 62

Recruiting

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

Neck Cancer

Russian Federation
BeiGene

Active, not recruiting

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent or Metastatic Nasopharyngeal Cancer

China, Taiwan, Thailand
Sierra Oncology LLC - a GSK company

Completed

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Advanced Solid Tumors

Spain, United Kingdom
Sirtex Medical

Completed

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Intrahepatic Cholangiocarcinoma

France, United Kingdom, Belgium, Australia, Spain, United States, Italy, Netherlands
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Active, not recruiting

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Recurrent or Metastatic

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Not yet recruiting

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Pancreatic Cancer

United States
Yung NA
Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern Hospital

Recruiting

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial

Muscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial Carcinoma

Hong Kong
Kansai Hepatobiliary Oncology Group

Unknown

A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis

Biliary Tract Cancer

Japan
Kansai Hepatobiliary Oncology Group

Completed

Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

Japan
Tianjin Medical University Cancer Institute and...

Recruiting

Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma (KEYSTONE-003)

Pembrolizumab | Neoadjuvant Chemotherapy | Adenocarcinoma of Esophagogastric Junction

China
Sun Yat-sen University

Recruiting

Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC

Nasopharyngeal Carcinoma | Circulating Tumor Cell | Effects of Chemotherapy | Distant Metastases.Clinical

China
Chuangzhen Chen

Recruiting

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer

Cervical Cancer | Neoadjuvant Chemotherapy

China
Incyte Corporation

Completed

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Breast Cancer | Multiple Myeloma | Gastric Cancer | Lung Cancer | Solid Tumor | Cholangiocarcinoma | Endometrial Cancer | Urothelial Cancer | Myeloproliferative Neoplasms | UC | MPN

United States, Denmark

Search clinical trials for: pembrolizumab, gemcitabine and cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations